<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>645</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15054081</PubmedId>
            <Abstract>BACKGROUND: The widespread threat of severe acute respiratory syndrome (SARS) to human health has made urgent the development of fast and accurate analytical methods for its early diagnosis and a safe and efficient antiviral vaccine for preventive use. For this purpose, we investigated the antigenicity of different regions of the SARS coronavirus (SARS-CoV) nucleocapsid (N) protein. METHODS: The widespread threat of severe acute respiratory syndrome (SARS) to human health has made urgent the development of fast and accurate analytical methods for its early diagnosis and a safe and efficient antiviral vaccine for preventive use. For this purpose, we investigated the antigenicity of different regions of the SARS coronavirus (SARS-CoV) nucleocapsid (N) protein.The cDNA for full-length N protein and its various regions from the SARS-CoV was cloned and expressed in Escherichia coli. After purification, all of the protein fragments were printed on glass slides to fabricate a protein microarray and then probed with the sera from SARS patients to determine the reactivity of these protein fragments. RESULTS: The widespread threat of severe acute respiratory syndrome (SARS) to human health has made urgent the development of fast and accurate analytical methods for its early diagnosis and a safe and efficient antiviral vaccine for preventive use. For this purpose, we investigated the antigenicity of different regions of the SARS coronavirus (SARS-CoV) nucleocapsid (N) protein.The cDNA for full-length N protein and its various regions from the SARS-CoV was cloned and expressed in Escherichia coli. After purification, all of the protein fragments were printed on glass slides to fabricate a protein microarray and then probed with the sera from SARS patients to determine the reactivity of these protein fragments.The full-length protein and two other fragments reacted with all 52 sera tested. Four important regions with possible epitopes were identified and named as EP1 (amino acids 51-71), EP2 (134-208), EP3 (249-273), and EP4 (349-422), respectively. EP2 and EP4 possessed linear epitopes, whereas EP1 and EP2 were able to form conformational epitopes that could react with most (&gt;80%) of the tested sera. EP3 and EP4 also formed conformational epitopes, and antibodies against these epitopes existed in all 52 of the sera tested. CONCLUSION: The widespread threat of severe acute respiratory syndrome (SARS) to human health has made urgent the development of fast and accurate analytical methods for its early diagnosis and a safe and efficient antiviral vaccine for preventive use. For this purpose, we investigated the antigenicity of different regions of the SARS coronavirus (SARS-CoV) nucleocapsid (N) protein.The cDNA for full-length N protein and its various regions from the SARS-CoV was cloned and expressed in Escherichia coli. After purification, all of the protein fragments were printed on glass slides to fabricate a protein microarray and then probed with the sera from SARS patients to determine the reactivity of these protein fragments.The full-length protein and two other fragments reacted with all 52 sera tested. Four important regions with possible epitopes were identified and named as EP1 (amino acids 51-71), EP2 (134-208), EP3 (249-273), and EP4 (349-422), respectively. EP2 and EP4 possessed linear epitopes, whereas EP1 and EP2 were able to form conformational epitopes that could react with most (&gt;80%) of the tested sera. EP3 and EP4 also formed conformational epitopes, and antibodies against these epitopes existed in all 52 of the sera tested.The N protein is a highly immunogenic protein of the SARS-CoV. Conformational epitopes are important for this protein, and antigenicity of the COOH terminus is higher than that of the NH(2) terminus. The N protein is a potential diagnostic antigen and vaccine candidate for SARS-CoV.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>988-95</ArticlePages>
            <ArticleTitle>Antigenicity analysis of different regions of the severe acute respiratory syndrome coronavirus nucleocapsid protein.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Zeliang</ForeName>
                </Author>
                <Author>
                    <LastName>Pei</LastName>
                    <ForeName>Decui</ForeName>
                </Author>
                <Author>
                    <LastName>Jiang</LastName>
                    <ForeName>Lingxiao</ForeName>
                </Author>
                <Author>
                    <LastName>Song</LastName>
                    <ForeName>Yajun</ForeName>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Jin</ForeName>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Hongxia</ForeName>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Dongsheng</ForeName>
                </Author>
                <Author>
                    <LastName>Zhai</LastName>
                    <ForeName>Junhui</ForeName>
                </Author>
                <Author>
                    <LastName>Du</LastName>
                    <ForeName>Zongmin</ForeName>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Bei</ForeName>
                </Author>
                <Author>
                    <LastName>Qiu</LastName>
                    <ForeName>Maofeng</ForeName>
                </Author>
                <Author>
                    <LastName>Han</LastName>
                    <ForeName>Yanping</ForeName>
                </Author>
                <Author>
                    <LastName>Guo</LastName>
                    <ForeName>Zhaobiao</ForeName>
                </Author>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>Ruifu</ForeName>
                </Author>
            </Authors>
            <Affiliations>Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.</Affiliations>
            <ArticleChemicalList>Antigens, Viral;DNA, Complementary;Epitopes;Nucleocapsid Proteins;nucleocapsid protein, Coronavirus</ArticleChemicalList>
            <ArticleMeshHeadingsList>Antigens, Viral(genetics; immunology); Cloning, Molecular; DNA, Complementary(genetics); Epitopes; Escherichia coli(metabolism); Humans; Nucleocapsid Proteins(biosynthesis; genetics; immunology); Protein Array Analysis; SARS Virus(immunology; isolation &amp; purification); Severe Acute Respiratory Syndrome(diagnosis)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>50</Volume>
                <Issue>6</Issue>
                <Title>Clinical chemistry</Title>
                <Issn>0009-9147</Issn>
                <MedlineTa>Clin Chem</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>EP1</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ASWFTALTQHGKEELRFPRGQ</LinearSequence>
                        <StartingPosition>51</StartingPosition>
                        <EndingPosition>71</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>ABI96968.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>694009</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>4838</EpitopeId>
                <ReferenceStartingPosition>51</ReferenceStartingPosition>
                <ReferenceEndingPosition>71</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 3</LocationOfData>
                        <BCellId>13559</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>550</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>52</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>52</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Sera were screened using a protein microarray analysis.  Purified protein fragments of varying lengths were screened and the authors used the results to deduce that this peptide region contains a potential epitope.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ASWFTALTQHGKEELRFPRGQ</LinearSequence>
                                        <StartingPosition>51</StartingPosition>
                                        <EndingPosition>71</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>ABI96968.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>694009</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>EP3</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KKSAAEASKKPRQKRTATKQYNVTQ</LinearSequence>
                        <StartingPosition>249</StartingPosition>
                        <EndingPosition>273</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>ABI96968.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>694009</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>31693</EpitopeId>
                <ReferenceStartingPosition>249</ReferenceStartingPosition>
                <ReferenceEndingPosition>273</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 3</LocationOfData>
                        <BCellId>13560</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>550</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>52</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>52</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Sera were screened using a protein microarray analysis.  Purified protein fragments of varying lengths were screened and the authors used the results to deduce that this peptide region contains a potential epitope.  The authors also suggest that this epitopic region may participate in the formation of a conformational epitope.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KKSAAEASKKPRQKRTATKQYNVTQ</LinearSequence>
                                        <StartingPosition>249</StartingPosition>
                                        <EndingPosition>273</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>ABI96968.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>694009</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

